We hypothesized that PMG5 may act to increase the efficacy of the Ad5-TRP2 vaccine by stimulating a local inflammatory environment, resulting in the increased accumulation of activated CD8+ T cells to the tumor site and/or creating a microenvironment that favors CD8+ T cell activity. This evidence concerns the gene CD8A and neoplasm.